Comorbid Social Phobia and Major Depressive Disorder: the Influence of Remission from Depression on Quality of Life and Functioning

2016 ◽  
Vol 12 (3) ◽  
pp. 719-736
Author(s):  
Alexander Joseph Steiner ◽  
Stephanie Marie Wright ◽  
Taylor Kuhn ◽  
Waguih William IsHak
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Social Phobia ◽  
Major Depressive

Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report

2021 ◽  
Author(s):  
Emma Morton ◽  
Venkat Bhat ◽  
Peter Giacobbe ◽  
Wendy Lou ◽  
Erin E. Michalak ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Repeated Measures ◽  
Short Form ◽  
Treatment Phase ◽  
Major Depressive ◽  
Symptomatic Remission ◽  
Substantial Degree

Abstract Introduction Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non-response; however, the impacts on quality of life (QoL) for individuals who receive this second-line treatment strategy have not been described. Methods We evaluated secondary QoL outcomes in patients with MDD (n=179). After 8 weeks of escitalopram, non-responders (<50% decrease in clinician-rated depression) were treated with adjunctive aripiprazole for 8 weeks (n=97); responders continued escitalopram (n=82). A repeated-measures ANOVA evaluated change in Quality of Life Enjoyment and Satisfaction Short Form scores. QoL was described relative to normative benchmarks. Results Escitalopram responders experienced the most QoL improvements in the first treatment phase. For non-responders, QoL improved with a large effect during adjunctive aripiprazole treatment. At the endpoint, 47% of patients achieving symptomatic remission still had impaired QoL. Discussion Individuals who were treated with adjunctive aripiprazole after non-response to escitalopram experienced improved QoL, but a substantial degree of QoL impairment persisted. Since QoL deficits may predict MDD recurrence, attention to ways to support this outcome is required.

scholarly journals C-QUALITY: Cost and Quality-of-Life Pharmacoeconomic Analysis of Antidepressants in Major Depressive Disorder in Italy

2013 ◽  
Vol 30 (7) ◽  
pp. 697-712 ◽  
Author(s):  
Claudio Mencacci ◽  
Eugenio Aguglia ◽  
Giovanni Biggio ◽  
Lodovico Cappellari ◽  
Guido Di Sciascio ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Pharmacoeconomic Analysis ◽  
Major Depressive ◽  
Quality Cost

The role of dopaminergic agents in improving quality of life in major depressive disorder

2009 ◽  
Vol 11 (6) ◽  
pp. 503-508 ◽  
Author(s):  
Waguih William IsHak ◽  
Michael Davis ◽  
Jessica Jeffrey ◽  
Konstantin Balayan ◽  
Robert N. Pechnick ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Dopaminergic Agents

scholarly journals Major depressive disorder in different age groups and quality of life

2017 ◽  
Vol 28 (2) ◽  
pp. 58-61 ◽  
Author(s):  
Umme Salma Talukder ◽  
MM Jalal Uddin ◽  
Niaz Mohammad Khan ◽  
Md Mostarshid Billah ◽  
Tufayel Ahmed Chowdhury ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Age Groups ◽  
World Health ◽  
Age Group ◽  
Major Depressive ◽  
World Health Organization Quality ◽  
Quality Of Life Scale

Major Depressive Disorder (MDD) is a significant public health problem due to its impact on the quality of life. The aim of the study was to determine the presentation of depression in different age group and quality of life among the respondents. This was a descriptive cross sectional study conducted from May, 2012 to February, 2013 among 65 patients aged 18 to 65 years with major depressive disorder in both outpatient and inpatient departments of National Institute of Mental Health (NIMH), Dhaka by using convenient sampling technique. Diagnostic and Statistical Manual of Mental Disorders- Text version (DSM-IV-TR), Beck Depression Inventory and World Health Organization Quality of Life Scale, Brief version (WHOQOL-BREF) were used to diagnose depressive disorder, to measure severity of depressive illness and Quality of Life (QOL) respectively. Level of depression was compared with the QOL. Quality of life deteriorated in patients with depression. Presence and level of depression was compared in different age groups of depressed patients. The results showed that most of the depressed people (17) were found in the age group of 21-25 years and most of the patients were severely depressed which was thirty nine (39). The study revealed that young people were mostly depressed and their quality of life was decreasing. lt needs further study to explore more information about pattern of presentation of depression and its effect on the quality of life.Bang J Psychiatry Dec 2014; 28(2): 58-61

Sign in / Sign up

Export Citation Format

Share Document